Bixby Bridge, BigSur, California, USA
of public and private funding,
$50M of which is dedicated to R&D
AstraZeneca, Pfizer, GlaxoSmithKline,
strategic and research partnerships
with university centres, hospitals, and
at different stages of development
(lead generation to clinical proof of concept)
and targeting various indications
(oncology, cardiovascular, pain, infectious diseases)
targeting unmet medical needs
supporting drug discovery efforts; one in
Saint-Laurent in the field of small chemical molecules, and the other in Laval in the field of biologics and vaccines
people and offering services
in medicinal chemistry, biological test development, pharmacokinetics, and metabolism, etc.
dedicated to the advancement of unique and potent epigenetic inhibitors for the targeted treatment of cancer.